ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
The Massachusetts Convention Center Authority is launching a new ferry route from Lovejoy Wharf to the Raymond L. Flynn ...
Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO Neal Koller will present at the following investor conferences during J.P.
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Particular Audience, the global leader in AI-powered retail media technology, has been named in Forrester Research's 2025 NRF Innovators Report. This analysis spotlights 50 companies at the forefront ...
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.
Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the ...